The Stromal Gene Encoding the CD274 Antigen As a Genetic Modifier Controlling Survival of Mice with γ-radiation-induced T-cell Lymphoblastic Lymphomas
Overview
Authors
Affiliations
Using an inter-specific subcongenic strain, Nested Recombinant Haplotype 3 (NRH3), generated between two mouse strains showing extreme differences in γ-radiation-induced thymic lymphoma susceptibility (SEG/Pas and C57BL/6J), we have identified a critical region on chromosome 19 that regulates survival of mice suffering from T-cell lymphoblastic lymphomas. Mapped on this region, the gene encoding the Cd274 ligand is able to trigger an inhibitory effect that modulates T-cell receptor (TCR) signalling and affects thymocyte maturation. Interestingly, this gene shows differential expression between thymic stromal cells from both strains in early response to a single sublethal γ-ray dose, but is inhibited in T-cell lymphoblastic lymphomas. Furthermore, we have identified several polymorphisms in the complementary DNA sequence of this gene that affect the affinity for its Cd279 receptor and are able to induce a differential rate of thymocyte apoptosis. Taken together, our data are consistent with Cd274 acting as a genetic modifier that influences the survival of γ-radiation-induced T-cell lymphoma-bearing mice. The data similarly support the idea of a co-evolution of tumour cells and associated stromal cells to generate a favourable microenvironment for T-cell lymphoma growth.
Ragazzini R, Boeing S, Zanieri L, Green M, DAgostino G, Bartolovic K Dev Cell. 2023; 58(22):2428-2446.e9.
PMID: 37652013 PMC: 10957394. DOI: 10.1016/j.devcel.2023.08.017.
CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Song Y, Song W, Li Z, Song W, Wen Y, Li J Front Oncol. 2020; 10:488.
PMID: 32391258 PMC: 7190811. DOI: 10.3389/fonc.2020.00488.
Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G Oncoimmunology. 2016; 5(11):e1196310.
PMID: 27999734 PMC: 5139638. DOI: 10.1080/2162402X.2016.1196310.
Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.
Aryankalayil M, Makinde A, Gameiro S, Hodge J, Rivera-Solis P, Palayoor S Radiat Res. 2014; 182(2):139-48.
PMID: 25003313 PMC: 4216662. DOI: 10.1667/RR13731.1.
Burgio G, Baylac M, Heyer E, Montagutelli X G3 (Bethesda). 2012; 2(10):1257-68.
PMID: 23050236 PMC: 3464118. DOI: 10.1534/g3.112.003285.